Macter International Limited (PSX: MACTER) has launched Hepanox (Enoxaparin Sodium) in a Pre-filled Syringe (PFS) format, expanding its biopharmaceuticals portfolio.
Hepanox PFS functions as a low molecular weight heparin (LMWH) anticoagulant. This addition strengthens Macter's footprint in the anticoagulant therapeutic segment and supports its long-term corporate growth strategy.
Read the full story on the original publisher’s website.
Open original article